Roles of macrophages in tumor development: a spatiotemporal perspective

Mathilde Bied, William W Ho, Florent Ginhoux, Camille Blériot

Read Roles of macrophages in tumor development: a spatiotemporal perspective by Mathilde Bied, William W Ho, Florent Ginhoux, Camille Blériot in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc10468537.txt.

Introduction

Bied, Ho, Ginhoux, and Blériot reviewed macrophages in tumours in 2023, tracing them across place and time. Macrophages are immune cells that keep tissues in balance. Inside tumours they pile up and tend to aid growth, in both the first tumour and its spreads. They are the most common immune cell in that zone.

Their sheer variety has slowed study for years. Bied lists the known subtypes and the job of each at each stage of cancer. Some subtypes ready a distant site before cancer cells arrive, paving a niche for spread. Others then feed the new tumour once it lands. Gaps in this map still block drugs that target these cells.

Catalog record

CREATORMathilde Bied, William W Ho, Florent Ginhoux, Camille Blériot
COLLECTIONPAPERS
FORMATTXT
FILE SIZE61 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC10468537

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Roles of macrophages in tumor development: a spatiotemporal perspective By Mathilde Bied, William W Ho, Florent Ginhoux, Camille Blériot Published in: Cellular and Molecular Immunology DOI: 10.1038/s41423-023-01061-6 ABSTRACT Abstract Macrophages are critical regulators of tissue homeostasis but are also abundant in the tumor microenvironment (TME). In both primary tumors and metastases, such tumor-associated macrophages (TAMs) seem to support tumor development. While we know that TAMs are the dominant immune cells in the TME, their vast heterogeneity and associated functions are only just being unraveled. In this review, we outline the various known TAM populations found thus far and delineate their specialized roles associated with the main stages of cancer progression. We discuss how macrophages may prime the premetastatic niche to enable the growth of a metastasis and then how subsequent metastasis-associated macrophages can support secondary tumor growth. Finally, we speculate on the challenges that remain to be overcome in TAM research. Keywords: Macrophages, Tumor associated macrophages, Tumor microenvironment, Metastasis Subject terms: Phagocytes, Immunosurveillance INTRODUCTION Macrophages are tissue-resident immune cells that emerge from multiple waves of hematopoiesis during embryonic development to seed their organs of residency [1]. In mice, primitive myeloid progenitors arise in the yolk sac around embryonic Day E7-8 and give rise to microglia, which are self-maintained locally from this initial seeding, independent of circulating monocytes [2]. A second semi-definitive wave of hematopoiesis starts at E8.25 and gives rise to progenitors that transiently shelter in the fetal liver, differentiate into monocyte-like cells [3, 4] that subsequently colonize fetal tissues to give rise to these cells are known as resident tissue macrophages (RTMs). A final, third wave of hematopoietic precursors emerges from the aorta-gonado-mesonephros region at E10.5 and leads to the generation of hematopoietic stem cells that will later establish definitive hematopoiesis in the fetal liver and then in the bone marrow. Monocytes from this third wave are recruited to tissues from late embryonic stages to adulthood, thus somewhat diluting the preexisting embryonic RTMs in a tissue-dependent manner [5]. Thus, contrary to early consensus [6], many RTMs found in adult tissues are long-lived cells with embryonic origins. During organogenesis, macrophages undergo tissue imprinting whereby embryonic progenitors first acquire a core macrophage differentiation program including pattern recognition and cytokine receptors [7]. Then, tissue-specific programs emerge during embryonic development with the differential activation of transcription factors and gene networks [7]. Such tissue imprinting is not an event restricted to embryonic development: as we draw on in this review, the relatively long lifespan of RTMs means that they are inevitably exposed to both non-homeostatic events, such as inflammation or infection, and systemic signals. The somewhat continuous imprinting that ensues as a result of a dynamically altered niche can lead to RTM dysregulation, which in turn might favor oncogenesis [8]. In the most basic sense, oncogenesis occurs as a result of an accumulation of mutations in oncogenes that permit normal cells to overcome restrictions on cellular replication such that they can grow without restraint to form a tumor. However, it is not only the tumor that has pathological consequences; other components that form the tumor microenvironment (TME) influence oncogenesis and cancer progression [9]. The TME comprises the blood and lymphatic vessels, extracellular matrix (ECM), and distinct host cells, including fibroblasts and immune cells, in the immediate ecosystem that surrounds the tumor, in addition to the tumor cells themselves [10]. Among the immune cellular components of the TME, macrophages have received particular attention. These so-called tumor-associated macrophages (TAMs) are typically the most abundant immune population within the TME, and their abundance is in fact now leveraged as a diagnostic marker, as it often correlates with prognosis [11–13]. In this review, we discuss the recent advances made in clarifying the roles of various populations of TAMs at key stages of cancer progression from tumor initiation to metastasis (Fig. 1). [Figure: Macrophages involved in tumor growth and metastasis. A In the primary tumor, tumor-associated macrophages favor tumor development. B Tissue-resident macrophages from distant tissues shape the pre-metastatic niche upon stimulation with tumor-derived factors such as extracellular vesicles to prepare cancer cell colonization. C As the cancer cells colonize the pre-metastatic niche, recruited monocytes give rise to metastatic-associated macrophages that fuel metastatic progression] MACROPHAGE DIVERSITY IN THE CANCER CONTEXT Macrophage diversity is broadly conceptualized through the prism of two antagonistic polarization states: pro-inflammatory M1 and anti-inflammatory M2 macrophages [14]. Upon the identification of TAMs in the TME, a similar paradigm was adopted with immunosuppressive TAMs clinically associated with a poor prognosis, considered M2 macrophages [15–17]. A therapeutic extension of this view has culminated in attempts to repolarize TAMs from the M2 to M1 state by acting on key modulators of macrophage biology, such as colony-stimulating factor 1 [18, 19] or IFN-γ [20]. Tumor-associated RTMs and monocyte-derived TAMs Although TAMs undoubtedly exhibit immunosuppressive properties, the M1/M2 paradigm does not fully reflect the extent of macrophage and TAM heterogeneity [21] and the different states of macrophage activation uncovered as a result of recent studies using single-cell and lineage-tracing technologies [22–27] (Table 1). Concerning their ontogeny, most TAMs are derived from circulating monocytes [28] and can almost completely overcome the pre-existing population of embryonically derived RTMs. A small population of native embryonic macrophages can, however, persist in the TME and have distinct functions from TAMs, including specific remodeling of the extracellular matrix [29]. More strikingly, a differential location within the TME has been revealed for pre-existing tumor-associated RTMs and monocyte-derived TAMs in various cancers, including breast cancer [30], non-small cell lung carcinoma [31], and glioma [32]. In both lung cancer [31] and glioma [32], embryonic-derived RTMs are found preferentially at the periphery of the tumor, while monocyte-derived TAMs infiltrate the tumor core. Nevertheless, monocyte-derived HO-1+ TAMs have also been shown to preferentially localize at the invasive margins of primary tumors and metastases in the MN-MCA1 murine model of cancer [33], therefore arguing for disease-specific localization of ontogenically distinct TAM populations. Altogether, these results suggest that such distinction between tumor-associated RTMs and monocyte-derived TAMs should be made when considering TAM identities and functions. [Table: Major TAM populations and their specificities] TAM FUNCTION IN PRIMARY TUMORS TAMs were originally considered remnants of an abortive immune response against the tumor [34]. However, in 2001, the Jeffrey Pollard group showed that mice with a recessive null mutation in the colony-stimulating factor 1 gene (Csf1op), the major macrophage growth factor, and genetically modified to develop mammary cancer had a delay in the development of metastatic carcinomas, therefore showing the involvement of macrophages in malignant progression of breast cancer [35]. These seminal findings have led to investigations into the mechanisms of these pro-tumoral roles of macrophages. We now know that within the TME, TAMs have several supporting functions that promote tumor development (Fig. 2), which we describe below. [Figure: Tumor-associated macrophages favor tumor development through different functions. TAMs have various roles in tumorigenesis and as such, interact closely with cancer cells and the TME. TAMs create a pro-tumoral immune environment by: inactivating cytotoxic T cells through PD-L1 expression; and producing various cytokines to recruit regulatory T cells (IL-6, IL-10 and TGF-ß) and create an inflammatory milieu (IL-6, IL- 1ß, CXCL8). TAMs shape the extracellular matrix by producing proteases such as matrix metalloproteinases or cathepsins that degrade collagen

Read the complete text